- Home
- Our Investigators
- Megan S. Bradley, MD
Megan S. Bradley, MD
Associate Professor, Department of Obstetrics, Gynecology & Reproductive Sciences, Division of Urogynecology & Reconstructive Pelvic Surgery
There are many disorders of the bladder that impact quality of life for women, especially with aging. An improved understanding of these disorders will not only impact care but also improve communication between patients and their providers.
Megan S. Bradley, MD
Research in Brief
Dr. Bradley’s research is focused on improving quality of life for aging women by refining how common urinary conditions are treated. Her clinical trials evaluate strategies such as whether antibiotics are always necessary for urinary tract infections and how to best dose therapies like Botox for overactive bladder. Her goal is to make treatment safer, more effective, and more personalized for older women.
Current Projects
- Principal Investigator, REDUCTION Trial: Empiric vs expectant management of UTIs in women over 70
- Co-investigator, RELIEF Trial: Comparing Botox dosing (50 vs 100 units) for overactive bladder in women aged 70+
- NIDDK-funded pilot trial: Culture-directed UTI treatment strategies
- Cystic Fibrosis Foundation-supported study: Urinary incontinence in women with cystic fibrosis
Selected Publications
- Dubinskaya A, Bradley MS, et al. Impact of prior prolapse repairs on surgical outcomes with minimally invasive sacral colpopexy. Int Urogynecol J. 2020. PMID: 32130464
- Clemens JQ, Bradley MS, et al. Prevalence, Subtypes, and Correlates of Nocturia. Neurourol Urodyn. 2020. PMID: 32249998
- Sassani JC, Artsen AM, Moalli PA, Bradley MS. Temporal Trends of Urogynecologic Mesh Reports to the FDA.Obstet Gynecol. 2020. PMID: 32282600
- Lenger SM, Bradley MS, et al. D-mannose vs other agents for recurrent UTI prevention. Am J Obstet Gynecol. 2020. PMID: 32497610
- Bradley MS, Cabrera C, et al. Sporadic compared to recurrent UTIs in older women. Neurourol Urodyn. 2020. PMID: 32803912
For additional publications, click here.